So, changing the protocol from preventing the progression of respiratory failure to recovery time (of those that recover), and increasing the number of patients in the trial is a good thing?
I don't really see how you are arriving at that, but I would like to hear your thoughts. Please elaborate.
At the very least this is pushing out the timeframe to trial completion, which is frustrating. It seems like both Lenzi and Leron are being delayed right now and it pisses me off. We need to get either or both of these to market.
News 
Market Data 
Discover 
AI
